Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, Naismith R, Naylor ML, Nicholas J, Rajbhandar R, Singh CM, Tintorè M, Zabalza A, Ziemssen T, Williams JR, Montalban X. Cohen JA, et al. Among authors: ziemssen t. Mult Scler. 2022 Jun;28(7):1131-1137. doi: 10.1177/13524585211061343. Epub 2022 Jan 7. Mult Scler. 2022. PMID: 34994577 Free PMC article.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E. Selmaj K, et al. Among authors: ziemssen t. Lancet Neurol. 2013 Aug;12(8):756-67. doi: 10.1016/S1474-4422(13)70102-9. Epub 2013 Jun 11. Lancet Neurol. 2013. PMID: 23764350 Clinical Trial.
Therapeutic decisions in multiple sclerosis: moving beyond efficacy.
Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. Brück W, et al. Among authors: ziemssen t. JAMA Neurol. 2013 Oct;70(10):1315-24. doi: 10.1001/jamaneurol.2013.3510. JAMA Neurol. 2013. PMID: 23921521 Free PMC article. Review.
Optimizing treatment success in multiple sclerosis.
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S. Ziemssen T, et al. J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705122 Free PMC article. Review.
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K. Kappos L, et al. Among authors: ziemssen t. JAMA Neurol. 2016 Sep 1;73(9):1089-98. doi: 10.1001/jamaneurol.2016.1451. JAMA Neurol. 2016. PMID: 27380540 Clinical Trial.
479 results